戻る Agenda
Oxford Debate: ‘This House Believes that Over-Engineered Clinical Development Has Inhibited Innovation’
Session Chair(s)
Julianne Hull, MS
CEO
WenStar Enterprises, United Kingdom
High-profile representatives from academia, industry, and patient organisations will debate both sides of this controversial hypothesis. Debaters will explore and argue the impact of regulations, budgets, quality, and patient needs.
Speaker(s)
Debater
Sir Martin Landray, PHD, FRCP
Protas, United Kingdom
Chief Executive
Michael Ryan
Syneos Health, United Kingdom
Vice President Strategic Accounts
Debater
Bettina Ryll
MPNE, Vision Zero Cancer, Sweden
Member of the First EU Cancer Mission Board
Debater
Sam Wadsworth, PHD
Dimension Therapeutics, United States
Chief Scientific Officer